Edwards Lifesciences 2025-26: TAVR +10.6%, FY26 Sales +8-10%
FY25 revenue $6.07B (+12%); op income $1.64B (+19%); NI $1.07B; EPS $1.83 (FY24 $6.97 included Critical Care divestiture gain). Q4 TAVR $1.16B (+10.6%); procedural growth high single digit. SAPIEN platform benefiting from Partner 3 seven-year + Partner 2 ten-year + early TAVR trial data + share gain from Boston Scientific exit. TMTT Q4 $156M (+40%+); FY >$500M; PASCAL + EVOQUE adoption + SAPIEN M3 mitral launch. Surgical Q4 $254M (+2%); FY $1B+ (+4.3%). FY26 guide: sales growth 8-10%; EPS $2.90-$3.05; Q1 sales $1.55-$1.63B; Q1 adj EPS $0.70-$0.76; ~$40M FX upside.
Key takeaways
-
TAVR +10.6% Q4 — re-acceleration on long-term durability data + share gain. Q4 global TAVR sales of $1.16B (+10.6%) marked a clear re-acceleration. Procedural growth in the quarter was high single digit. Multiple drivers converging: (a) Partner 3 seven-year + Partner 2 ten-year long-term durability data validating SAPIEN platform, (b) early TAVR trial results expanding the addressable patient population, (c) sticky share gain from Boston Scientific's exit of the TAVR market (announced earlier), (d) SAPIEN 3 Ultra Resilia adoption. The combination of clinical data + share gain + platform broadening creates multi-year compounding tailwinds.
-
TMTT Q4 +40%+ to $156M; FY >$500M — second growth pillar emerging. Transcatheter Mitral and Tricuspid Therapies (TMTT) crossed $500M FY revenue with Q4 +40%+ growth — well-defined inflection. Drivers: (a) global PASCAL + EVOQUE adoption (the established mitral + tricuspid platforms), (b) launch of SAPIEN M3 expanding the mitral portfolio, (c) NextGen PASCAL + PASCAL for US tricuspid patients on the horizon. TMTT is now a multi-hundred-million franchise growing 40%+ — a meaningful contribution to total growth.
-
FY26 guide: sales growth 8-10%; EPS $2.90-$3.05 — sustained mid-single-digit-plus EPS. Sales growth 8-10% with EPS guide $2.90-$3.05. Q1 sales guide $1.55-$1.63B; adj EPS $0.70-$0.76. ~$40M FX upside vs prior year. Confidence drivers: TAVR NCD update potential expanding reimbursement, new therapy launches, continued TMTT adoption.
-
Surgical FY $1B+ (+4.3%); RESILIA therapies driving mid-single-digit FY26 growth. Surgical FY sales >$1B (+4.3%); Q4 surgical $254M (+2%, impacted by end-of-year distributor inventory adjustments in one country). Mid-single-digit growth expected in FY26 driven by RESILIA therapies (next-gen tissue valves with longer durability data). Steady franchise providing diversification + a fundamental floor.
-
Strategic positioning: structural heart leader + Boston Scientific exit + AHA partnership. EW continues to lead structural heart globally. The Boston Scientific TAVR exit removed a major competitor + reduced future competitive pressure. Partnership with American Heart Association for heart valve initiative drives diagnosis + treatment improvement. Multi-year clinical evidence build-out (Partner trials + early TAVR + guideline changes) supports proactive disease management messaging globally. Structural advantages compound over time.
Business
Edwards Lifesciences Corporation is the global leader in structural heart disease therapies, with three core franchises:
- TAVR (Transcatheter Aortic Valve Replacement) (~75% of revenue): SAPIEN 3 / Ultra / Ultra Resilia platforms. Treatment for severe aortic stenosis. Q4 sales $1.16B (+10.6%); FY ~$4.5B+ at this run-rate. Largest franchise + dominant share.
- TMTT (Transcatheter Mitral and Tricuspid Therapies) (~10% of revenue, fastest growing): PASCAL + EVOQUE + SAPIEN M3. Q4 +40%+ to $156M; FY >$500M. NextGen PASCAL + PASCAL for US tricuspid patients in pipeline.
- Surgical (~15% of revenue): RESILIA tissue valves + traditional surgical heart valves. Q4 $254M (+2%); FY $1B+ (+4.3%). Steady franchise.
Strategic moves FY25:
- TAVR Q4 re-acceleration to +10.6% on share gain + clinical data
- TMTT crossing $500M FY (+40%+ Q4) — second growth franchise emerging
- SAPIEN 3 Ultra Resilia adoption
- SAPIEN M3 mitral platform launch
- Partner 3 seven-year + Partner 2 ten-year long-term data
- Early TAVR trial expansion potential
- Boston Scientific TAVR market exit — share gain
- AHA heart valve initiative partnership
- Critical Care divestiture (largely impact in FY24, FY25 NI normalized lower)
- $-893M FY25 buyback (vs $-1.16B FY24)
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 5.38 | 5.01 | 5.44 | 6.07 |
| Revenue YoY | n/a | -7% | +9% | +12% |
| Op income ($B) | 1.70 | 1.43 | 1.38 | 1.64 |
| Op margin | 31.6% | 28.5% | 25.3% | 27.0% |
| Net income ($B) | 1.52 | 1.40 | 4.17 | 1.07 |
| Diluted EPS ($) | 2.44 | 2.30 | 6.97 | 1.83 |
| FCF ($B) | 0.95 | 0.63 | 0.29 | 1.34 |
| Capex ($M) | -265 | -266 | -252 | -260 |
| Total debt ($M) | 691 | 685 | 700 | 705 |
| Buyback ($M) | -1,727 | -880 | -1,159 | -893 |
| Dividends ($M) | 0 | 0 | 0 | 0 |
Note: FY24 NI $4.17B + EPS $6.97 reflect Critical Care segment divestiture gain (large one-time gain). FY25 EPS $1.83 reflects normalized run-rate without that gain. Excluding the Critical Care divestiture impact, underlying earnings progression has been steady.
The earnings progression: FY23 was a soft year (revenue -7%); FY24 reaccelerated (+9%); FY25 +12% reflects TAVR + TMTT growth + Critical Care divestiture-adjusted comp. Op margin recovered to 27% (FY25) after compression to 25.3% (FY24). FCF $1.34B FY25 (vs $0.29B FY24) — major improvement.
Total debt $705M — minimal leverage; net cash position. EW does not pay a dividend; capital return is buyback-only.
Capital allocation
- Capex: $-260M FY25 (+3% YoY).
- Dividends: $0 (no dividend; capital return via buyback only).
- Buybacks: $-893M FY25 (-23% YoY from $1.16B FY24).
- Total debt: $705M (modest, +1% YoY); net cash position.
- FCF: $1.34B FY25.
FY26 outlook (per Q4 2025 call, 2026-02-10)
| FY26 framework | Detail |
|---|---|
| Sales growth | 8% to 10% |
| EPS | $2.90 to $3.05 |
| Q1 sales | $1.55B to $1.63B |
| Q1 adjusted EPS | $0.70 to $0.76 |
| FX impact | ~$40M upside vs prior year |
| Surgical | Mid-single-digit (RESILIA driver) |
| TMTT | Continued strong growth |
| TAVR | NCD update potential |
Management cited confidence in meeting guidance via growth catalysts: TAVR NCD update potential expanding reimbursement coverage, TMTT new therapy launches, continued international + procedural growth, and AHA partnership amplifying patient access.
Key risks
TAVR competitive landscape. While Boston Scientific's exit removed a major competitor, Medtronic remains a strong competitor in TAVR. Other emerging entrants + technology evolution (next-gen platforms) create ongoing competitive monitoring.
SAPIEN platform reliance. TAVR is ~75% of revenue and dominantly SAPIEN-platform. Any product issue, recall, or clinical data setback in SAPIEN can disproportionately impact total business.
TMTT execution. TMTT is the fastest-growing franchise but in early-stage adoption. Continued procedural training, hospital adoption, reimbursement expansion all need to track. Potential adoption headwinds in select markets.
Reimbursement / NCD dynamics. TAVR + TMTT depend on Medicare + private insurer reimbursement decisions (NCDs in US, equivalent processes globally). Potential expansion (e.g., asymptomatic / earlier-stage AS via early TAVR data) is upside; unexpected restrictions are downside.
Clinical data outcomes. Multi-year clinical trials (Partner series, early TAVR, etc.) drive guideline + reimbursement decisions. Negative or equivocal trial readouts can pressure adoption + share.
International expansion / FX. Global revenue mix exposes EW to FX volatility. Emerging market expansion has growth potential but currency + geopolitical / regulatory risks.
Surgical sub-segment dynamics. Surgical valve market is shifting toward TAVR; surgical growth can be pressured by procedure mix shift. RESILIA + next-gen tissue valves help defend, but secular dynamic needs management.
Manufacturing + supply chain. Multi-year capacity investments + supply chain reliability matter for product availability. Any disruption affects revenue + procedural growth.
Pricing / discounting pressure. Hospital systems consolidating purchasing power + GPOs creating ongoing pricing pressure on med-tech device pricing.
Litigation + product liability. Implanted devices carry multi-year product liability exposure.
Regulatory landscape. FDA + EMEA + CFDA + other regulators all matter for new product approvals + label expansions. Multi-region regulatory navigation complex.
Hospital capital + procedural volume. TAVR + TMTT are elective procedures dependent on hospital capacity + capital + procedural volumes. Any environment that disrupts elective procedures (similar to COVID) creates near-term volatility.
Bottom line
Edwards Lifesciences FY25 is the multi-franchise re-acceleration year: revenue +12% to $6.07B; op income +19% to $1.64B; op margin 27.0% (recovering from 25.3% FY24). Q4 TAVR $1.16B (+10.6%) — clean re-acceleration on long-term durability data + Boston Scientific exit share gain + SAPIEN 3 Ultra Resilia adoption. TMTT Q4 +40%+ to $156M; FY >$500M — second growth franchise establishing. Surgical Q4 $254M (+2%) / FY $1B+ (+4.3%). FCF $1.34B; buyback $893M.
FY26 guide: sales growth 8-10%; EPS $2.90-$3.05; Q1 $1.55-$1.63B / $0.70-$0.76; FX ~$40M upside. Continued multi-franchise growth + TAVR NCD update potential + TMTT acceleration.
The risks are real — TAVR competitive landscape (Medtronic primarily), SAPIEN platform reliance, TMTT early-stage adoption execution, reimbursement / NCD dynamics, clinical data outcomes, international expansion / FX, surgical sub-segment dynamics (procedure mix shift), manufacturing + supply chain, pricing / discounting pressure, litigation + product liability, regulatory landscape, hospital capital + procedural volume.
But the structural thesis (global structural heart leader + TAVR market dominance + ~75% revenue TAVR + Boston Scientific competitive exit + Partner 3 seven-year + Partner 2 ten-year + early TAVR trial data + TMTT $500M+ franchise emerging at +40% growth + SAPIEN M3 mitral expansion + RESILIA next-gen surgical tissue valves + AHA partnership + multi-year clinical evidence + minimal leverage + buyback program) is intact and FY25 confirms.
Quality global structural heart compounder mid-cycle, with multi-franchise growth + clinical evidence depth + share gain + reimbursement expansion potential. The TAVR Q4 +10.6% + TMTT +40%+ + surgical RESILIA driver + FY26 +8-10% sales guide + EPS $2.90-$3.05 + multi-year clinical data flow + Boston Scientific exit creates one of the cleaner structural heart compounding setups for investors seeking exposure to large-and-growing structural heart disease therapies + clinical innovation + procedural medicine. The conservative FY26 framework + TMTT inflection + TAVR NCD update potential + multi-year platform investment provides multiple paths to outperformance over a multi-year horizon. TAVR competitive dynamics + reimbursement landscape + clinical readouts remain ongoing risks, but the franchise diversification + clinical evidence depth + dominant TAVR position + TMTT growth runway support continued compounding through cycles.
Citations
- Edwards Lifesciences Corporation FY25 Form 10-K (filed February 2026, SEC EDGAR).
- EW Q4 2025 earnings call, 2026-02-10 — Q4 TAVR $1.16B (+10.6%, procedural high single digit); SAPIEN platform supported by Partner 3 seven-year + Partner 2 ten-year + early TAVR trial; SAPIEN 3 Ultra Resilia adoption; Boston Scientific exit share gain; TMTT Q4 $156M (+40%+); FY >$500M; PASCAL + EVOQUE adoption; SAPIEN M3 mitral launch; NextGen PASCAL + PASCAL US tricuspid catalysts; Surgical Q4 $254M (+2%, distributor inventory adjustment in one country); FY $1B+ (+4.3%); FY26 sales growth 8-10%; EPS $2.90-$3.05; Q1 sales $1.55-$1.63B; Q1 adj EPS $0.70-$0.76; ~$40M FX upside.
- EW Q3 / Q2 / Q1 2025 earnings calls — supporting TAVR + TMTT + surgical trajectory and franchise dynamics.
- Internal financial_statements view (consolidated annual + cash flow + capital structure).